RS58945B1 - Derivati benzodioksola kao inhibitori fosfodiesteraze - Google Patents

Derivati benzodioksola kao inhibitori fosfodiesteraze

Info

Publication number
RS58945B1
RS58945B1 RS20190851A RSP20190851A RS58945B1 RS 58945 B1 RS58945 B1 RS 58945B1 RS 20190851 A RS20190851 A RS 20190851A RS P20190851 A RSP20190851 A RS P20190851A RS 58945 B1 RS58945 B1 RS 58945B1
Authority
RS
Serbia
Prior art keywords
compound
ethanone
dermatitis
spiro
psoriasis
Prior art date
Application number
RS20190851A
Other languages
English (en)
Serbian (sr)
Inventor
Simon Feldbæk Nielsen
Original Assignee
Leo Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leo Pharma As filed Critical Leo Pharma As
Publication of RS58945B1 publication Critical patent/RS58945B1/sr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4433Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
RS20190851A 2010-06-24 2011-06-24 Derivati benzodioksola kao inhibitori fosfodiesteraze RS58945B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35820910P 2010-06-24 2010-06-24
EP16020112.5A EP3070091B1 (en) 2010-06-24 2011-06-24 Benzodioxole derivatives as phosphodiesterase inhibitors

Publications (1)

Publication Number Publication Date
RS58945B1 true RS58945B1 (sr) 2019-08-30

Family

ID=44351701

Family Applications (2)

Application Number Title Priority Date Filing Date
RS20190851A RS58945B1 (sr) 2010-06-24 2011-06-24 Derivati benzodioksola kao inhibitori fosfodiesteraze
RS20160581A RS55104B1 (sr) 2010-06-24 2011-06-24 Heterociklična jedinjenja benzodioksola ili benzodioksepina kao inhibitori fosfodiesteraze

Family Applications After (1)

Application Number Title Priority Date Filing Date
RS20160581A RS55104B1 (sr) 2010-06-24 2011-06-24 Heterociklična jedinjenja benzodioksola ili benzodioksepina kao inhibitori fosfodiesteraze

Country Status (29)

Country Link
US (3) US8980905B2 (enExample)
EP (2) EP3070091B1 (enExample)
JP (2) JP6174997B2 (enExample)
KR (1) KR101864578B1 (enExample)
CN (1) CN102958937B (enExample)
AU (1) AU2011269429B2 (enExample)
BR (1) BR112012032813B1 (enExample)
CA (1) CA2802895C (enExample)
CY (2) CY1117862T1 (enExample)
DK (2) DK3070091T3 (enExample)
ES (2) ES2733092T3 (enExample)
HR (2) HRP20160919T1 (enExample)
HU (2) HUE030081T2 (enExample)
IL (1) IL223329A (enExample)
LT (2) LT3070091T (enExample)
MX (1) MX2012014131A (enExample)
MY (1) MY157481A (enExample)
NZ (1) NZ603895A (enExample)
PL (2) PL2585469T3 (enExample)
PT (2) PT3070091T (enExample)
RS (2) RS58945B1 (enExample)
RU (1) RU2583787C2 (enExample)
SG (1) SG186140A1 (enExample)
SI (2) SI3070091T1 (enExample)
TR (1) TR201909709T4 (enExample)
TW (1) TWI507410B (enExample)
UA (1) UA109140C2 (enExample)
WO (1) WO2011160632A1 (enExample)
ZA (1) ZA201209031B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9855285B2 (en) * 2012-11-30 2018-01-02 Leo Pharma A/S Method of inhibiting the expression of IL-22 in activated T-cells
CA2953284A1 (en) * 2014-06-23 2015-12-30 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
CA3007432A1 (en) * 2015-12-18 2017-06-22 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
WO2018234299A1 (en) * 2017-06-20 2018-12-27 Leo Pharma A/S Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
CN111727191B (zh) 2017-12-15 2024-01-05 联合疗法公司 取代的氮杂环丁烷二氢噻吩并吡啶类化合物及其作为磷酸二酯酶抑制剂的用途
US11919912B2 (en) 2018-05-21 2024-03-05 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
IL284815B2 (en) * 2019-01-15 2025-10-01 Union Therapeutics As Modified-release tablet formulations containing phosphodiesterase inhibitors
EP4003343A1 (en) * 2019-07-24 2022-06-01 Constellation Pharmaceuticals, Inc. Ezh2 inhibition in combination therapies for the treatment of cancers
CN112552276B (zh) * 2019-09-25 2023-03-21 中国科学院上海药物研究所 苯并氧杂卓-5-酮类化合物及其制备方法和用途
AU2022245186A1 (en) 2021-03-22 2023-10-05 UNION therapeutics A/S Treatment of hidradenitis suppurativa with orismilast
GB202205715D0 (en) 2022-04-19 2022-06-01 Union Therapeutics As Treatment of neutrophilic dermatoses
GB202306662D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Dosage regimen
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100331255B1 (ko) 1993-07-02 2002-10-25 빅굴덴 롬베르그 케미쉐 화부리크 게엠베하 플루오로알콕시-치환된벤즈아미드및시클릭뉴클레오티드포스포디에스테라아제억제제로서의그의용도
GB9507297D0 (en) 1995-04-07 1995-05-31 Rh Ne Poulenc Rorer Limited New composition of matter
AU705690B2 (en) 1995-05-19 1999-05-27 Kyowa Hakko Kogyo Co. Ltd. Oxygen-containing heterocyclic compounds
CA2252537A1 (en) * 1996-05-20 1997-11-27 Darwin Discovery Limited Benzofuran carboxamides and their therapeutic use
WO1998022455A1 (en) 1996-11-19 1998-05-28 Kyowa Hakko Kogyo Co., Ltd. Oxygenic heterocyclic compounds
JP2005060375A (ja) * 2003-07-28 2005-03-10 Kyowa Hakko Kogyo Co Ltd 含酸素複素環化合物
DE10360792A1 (de) 2003-12-23 2005-07-28 Grünenthal GmbH Spirocyclische Cyclohexan-Derivate
EA014956B1 (ru) * 2004-12-17 2011-04-29 ГЛЕНМАРК ФАРМАСЬЮТИКАЛС Эс.Эй. Гетероциклические соединения, применяемые для лечения воспалительных и аллергических нарушений
UA98639C2 (en) * 2007-02-28 2012-06-11 Лео Фарма А/С Phosphodiesterase inhibitors
JP5501770B2 (ja) * 2007-02-28 2014-05-28 レオ ファーマ アクティーゼルスカブ 新規ホスホジエステラーゼ阻害剤
PT2794603T (pt) * 2011-12-21 2016-07-26 Leo Pharma As [1,2,4] triazolopiridinas e seu uso como inibidores de fosfodiesterase

Also Published As

Publication number Publication date
HRP20160919T1 (hr) 2016-10-07
DK3070091T3 (da) 2019-07-08
EP3070091B1 (en) 2019-04-17
EP3070091A1 (en) 2016-09-21
ES2584055T3 (es) 2016-09-23
HUE044301T2 (hu) 2019-10-28
IL223329A0 (en) 2013-02-03
NZ603895A (en) 2014-10-31
RU2583787C2 (ru) 2016-05-10
MY157481A (en) 2016-06-15
UA109140C2 (uk) 2015-07-27
DK2585469T3 (en) 2016-08-29
RU2013103079A (ru) 2014-07-27
RS55104B1 (sr) 2016-12-30
SI3070091T1 (sl) 2019-08-30
BR112012032813A2 (pt) 2016-11-08
IL223329A (en) 2017-01-31
TWI507410B (zh) 2015-11-11
HK1182699A1 (zh) 2013-12-06
HUE030081T2 (en) 2017-04-28
ES2733092T3 (es) 2019-11-27
HRP20191136T1 (hr) 2019-09-20
WO2011160632A1 (en) 2011-12-29
CN102958937B (zh) 2016-03-30
LT3070091T (lt) 2019-07-25
US20150111915A1 (en) 2015-04-23
US8980905B2 (en) 2015-03-17
CY1122201T1 (el) 2020-11-25
CY1117862T1 (el) 2017-05-17
AU2011269429B2 (en) 2015-07-09
EP2585469B1 (en) 2016-05-25
BR112012032813B1 (pt) 2022-02-01
US9637499B2 (en) 2017-05-02
JP2016164168A (ja) 2016-09-08
TR201909709T4 (tr) 2019-07-22
TW201206940A (en) 2012-02-16
KR101864578B1 (ko) 2018-06-07
LT2585469T (lt) 2016-10-10
ZA201209031B (en) 2014-02-26
CA2802895A1 (en) 2011-12-29
SG186140A1 (en) 2013-01-30
US20130123291A1 (en) 2013-05-16
PT2585469T (pt) 2016-08-29
PT3070091T (pt) 2019-07-22
JP2013529602A (ja) 2013-07-22
KR20130038341A (ko) 2013-04-17
EP2585469A1 (en) 2013-05-01
PL3070091T3 (pl) 2019-09-30
US20160022657A1 (en) 2016-01-28
MX2012014131A (es) 2013-01-29
CA2802895C (en) 2019-05-21
SI2585469T1 (sl) 2016-11-30
PL2585469T3 (pl) 2017-07-31
AU2011269429A1 (en) 2012-12-20
CN102958937A (zh) 2013-03-06
JP6174997B2 (ja) 2017-08-02
US9273064B2 (en) 2016-03-01

Similar Documents

Publication Publication Date Title
RS58945B1 (sr) Derivati benzodioksola kao inhibitori fosfodiesteraze
RS66506B1 (sr) Jedinjenje agonista glp-1r receptora i njegova upotreba
RU2495043C2 (ru) Новые ингибиторы фосфодиэстераз
CA3202111A1 (en) Cannabinoid derivatives as pharmaceutically active compounds and method of preparation thereof
RU2630699C2 (ru) [1,2,4]триазолопиридины и их применение в качестве ингибиторов фосфодиэстеразы
CN110372665A (zh) 一种阿哌沙班吡啶酮杂质的制备方法
HK1182699B (en) Benzodioxole or benzodioxepine heterocyclic compounds phosphodiesterase inhibitors
TWI432439B (zh) 新穎磷酸二酯酶抑制劑
NZ625849B2 (en) [1,2,4]triazolopyridines and their use as phosphodiesterase inhibitors
JPWO2017073710A1 (ja) モルヒナン誘導体及びその医薬用途
TW201329060A (zh) 做為trpv3調節劑的色原烷衍生物